NEW YORK (AP) -- Shares of molecular diagnostics company Cepheid rose Tuesday after the company said that demand for several of its GeneXpert tests were stronger than expected. THE SPARK: Cepheid said ...

What: Shares of Cepheid (NASDAQ: CPHD), a molecular diagnostics company, fell by more than 20% today on heavy volume after the company released its preliminary third quarter results. Digging into the ...

Investors in Cepheid (NASD: CPHD) saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPHD options ...

Add Yahoo as a preferred source to see more of our stories on Google. By Natalie Grover (Reuters) - Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 ...

Cepheid (Nasdaq:CPHD) hit a new 52-week high Friday as it changed hands at $27.05 compared with its previous 52-week high of $27. Cepheid is currently trading at $27.05 with 15,126 shares changing ...

Investors in Cepheid (NASD: CPHD) saw new options become available this week, for the March 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...

Cepheid [CPHD], a leading molecular diagnostics company and the developer of Xpert MTB/RIF, the rapid diagnostic test for Tuberculosis which was endorsed by the World Health Organization, will visit ...